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Aims: Acute Graft-versus-host disease (aGVHD) is a leading cause of morbidity 
and mortality following allogeneic haematopoietic stem cell transplantation 
(HSCT). The aim of this study was to evaluate the clinical utility of a composite 
biomarker panel to help identify individuals at risk of developing aGVHD, and to 
help predict and differentiate between severity of aGVHD following T-cell deplet-
ed allogeneic HSCT.  
Methods: We retrospectively analyzed our cohort of biopsy confirmed aGVHD 
patients, who underwent T-cell deplete HSCT and matched them with negative 
controls without any evidence of aGVHD. Post-transplant serum samples on day 
0,+7 and at onset of aGVHD were analyzed for Elafin, regenerating islet-derived 
3-α (REG3α), soluble tumour necrosis factor receptor-1 (sTNFR1), soluble inter-
leukin-2 receptor-α (sIL-2Rα) and hepatocyte growth factor (HGF). Biomarker da-
ta was combined as composite panels A-F (Table 2) using logistic regression 
analysis. Receiver Operating Characteristic (ROC) analysis was performed to 
study sensitivity and specificity of the composite panels. 
Results: Our composite biomarker panels significantly differentiated between 
aGVHD and no GVHD patients at time of onset (Panel E) and reliably predicted 
severity of GVHD grades at Day 0 and 7 post-transplant (Panel B and D). The 
area under the curve (AUC) for the composite panel at time of onset was 0.65 
with specificity, sensitivity, positive and negative predictive values of 100%, 
55.6%, 100% and 78.9%, respectively (p=0.03).  
Conclusions: This pilot data supports the usefulness of these composite bi-
omarker panels in the prediction of severity and diagnosis of acute GVHD in pa-
tients undergoing T-cell depleted reduced intensity allogeneic HSCT.  
 
Page 3 of 31
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
  4 
INTRODUCTION 
Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially cura-
tive treatment for a range of malignant and non-malignant haematological dis-
eases. However, its use is limited by several complications including aberrant 
immune response by allo-reactive T-cells causing acute and chronic graft-versus-
host disease (GVHD). The incidence of GVHD varies enormously from 10-80% 
depending on risk factors such as degree of human leukocyte antigen (HLA) dis-
parity, graft source, conditioning regimen (standard myeloablative or reduced in-
tensity; with or without T-cell depletion), CMV sero-status, recipient age, GVHD 
prophylaxis regimen, donor parity and sex mis-match1–6. 
 
 
The diagnosis of acute GVHD (aGVHD) remains mainly clinical, supplemented 
by biopsy where possible7,8. The skin is the most commonly involved organ and 
presentation can range from a limited maculopapular rash on the palms and 
soles to widespread skin involvement with muco-cutaneous ulceration and bullae 
formation. Similarly, other organs such as gastro-intestinal (GI) tract and liver can 
be involved and the symptoms range from mild to severe.  Histology can be help-
ful but the findings are often non-specific9. 
Currently, there are no established biomarkers that can reliably diagnose, assess 
prognosis, or have any target organ-specificity of aGVHD10,11. However, im-
portant advances have been made in biomarker biology with potential clinical ap-
plications in aGVHD settings11. Hepatocyte growth factor (HGF) is a cytokine se-
creted by the mesenchymal cells as a physiological response to hepatic and in-
testinal damage and significantly higher concentrations were found in patients 
who developed severe aGVHD12. 
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  5 
Soluble tumour necrosis factor alpha (TNFα) concentrations are higher in 
patients with aGVHD and positively correlated with its severity in some studies13–
16 whereas other studies did not support this relationship5,13,17,18. Soluble TNF re-
ceptor 1 (sTNFR1) is present in nanogram concentrations in a very stable state13 
and has been associated with severity of aGVHD in most studies5,19,20. Increased 
sTNFR1 at day 7 after HSCT was associated with the severity of GVHD and 
treatment related mortality19,21. 
 
Activated donor T cells express interleukin 2 receptor (IL-2R), which contains 
three subunits: α, β and γ, on their cell membrane22,23. Interleukin 2 (IL-2) binds 
to the β-subunit and is subsequently internalized and the α-subunit is shed from 
the cell surface and found in plasma as sIL-2Rα23,24. Increased sIL-2Rα concen-
trations were noted in aGVHD patients and closely correlated with GVHD severi-
ty11,25,26.  
 
Regenerating islet-derived 3-α (REG3α) is an antimicrobial protein secreted by 
Paneth cells27 and a promising biomarker of lower GI aGVHD. Elafin is an elas-
tase inhibitor overexpressed in inflamed epidermis28,29 and is induced by inflam-
matory cytokines that mediate GVHD20,30. Increased elafin concentrations were 
noted at the onset of cutaneous aGVHD and closely correlated with aGVHD se-
verity. It was also noted as a prognostic marker because of its association with 
non-relapse mortality (NRM) and overall survival (OS)30. 
 
These biomarkers have been studied in the context of T-replete allogeneic HSCT 
but data is lacking in the T-depleted setting. The aim of this study was to evaluate 
the clinical utility of composite biomarker panel consisting of HGF, Elafin, sIL-
2Rα , sTNFR1, and REG3α  in T-depleted allogeneic HSCT. 
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METHODS 
 
Study population 
This study is a retrospective analysis of a subset of allogeneic HSCT patients 
from the invasive aspergillosis study by Ceesay et al31 (ClinicalTrials.gov No. 
NCT00816088; REC no: 08/HA0808/154) with full ethical approval. Patients were 
included if they had biopsy-confirmed diagnosis of aGVHD within 100 days of 
transplantation. These patients were then matched (age, sex, underlying haema-
tological diagnosis, time since transplant, and conditioning regimen) with other 
allogeneic HSCT recipients who had no evidence of aGVHD. A total of 26 pa-
tients were included in the current study (12 confirmed aGVHD and 14 matched 
negative controls). Grading of aGVHD was according to Modified Seattle Glucks-
berg criteria8.  
Transplant conditioning protocols were either Alemtuzumab or Anti-thymocyte 
Globulin (ATG)-based (in vivo- T cell depletion) regimens. None of the patients 
had any evidence of infection at the time of sample collection.  
 
 
Blood Samples and biomarker measurements 
Serum samples at days 0 and 7 post-transplant and at the time of onset of 
aGVHD were evaluated for the biomarker panel (HGF, Elafin, sIL-2Rα , sTNFR1, 
and REG3α). HGF, sTNFR1 and sIL-2Rα were analysed using enzyme-linked 
immunosorbent assay (ELISA) methods from R&D Systems (Abingdon, Oxford-
shire, UK).  Elafin was measured using an ELISA method from Abcam (Cam-
bridge, UK) and REG3α was measured using an ELISA method from Cloud-
Clone (Yuhan, China).   The assays for purpose of this study were carried out us-
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  7 
ing ELISA plates for 5 biomarkers on three different days in duplicates with 
standard internal quality control (IQC) to limit inter-assay variation, corresponding 
to samples from day 0, day 7 post HSCT and at time of aGVHD onset in batches. 
The methods used for estimation of these biomarkers were internally validated 
before using them to measure clinical patients’ samples. All patient samples were 
run in duplicate and coefficient of variance (CV) between duplicate samples was 
<10%. All method validation studies including precision, linearity, recovery, stabil-
ity, carry over/under and lower limit of detection were duly carried out.  
 
Each of these results performed in the study were reviewed by clinical biochem-
ists following internal laboratory validation, median results were reviewed and 
correlated with clinical picture of the study patients following sample collection, 
although limited by retrospective nature of the study.  
 
Statistical Analysis 
Statistical analysis including ROC analysis was performed using Analyse-It ver-
sion 2 (Leeds, UK). Data were tested for normality using the Shapiro-Wilk W test 
with a confidence interval of 95%. Patient characteristics were compared by chi-
square test or Mann Whitney U test.  
 
Logistic regression was performed using SigmaXL version 7 (Kitchener, Canada) 
to develop a composite panel of biomarkers (Panel A-F; Table 1). Binary logistic 
regression was used for a composite panel to discriminate between no GVHD 
and GVHD biopsy positive patients. Ordinal logistic regression was used to de-
velop a composite panel for differentiating grading of GVHD. The best three 
markers with most significant p value were included to produce the best fit model.  
Page 7 of 31
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
  8 
Each equation of the composite panels differs based on different time-points of 
samples analysed, grade of aGVHD and dependent on statistically significant 
coefficient estimates of each panel. Numerical data were reported as median 
and inter-quartile range (IQR). A p value ≤ 0.05 was taken as statistically signifi-
cant using logistical regression modelling. 
 
To evaluate the reproducibility of the accuracy obtained in the composite panel 
and uncertainty around it, we conducted bootstrap (random subsampling from the 
same underlying population) cross-validation with 1000 replications to determine 
95% confidence interval (CI) for the area under the curve (AUC). 
 
Receiver Operating Characteristic curves (ROC) analysis was performed to 
evaluate the sensitivity and specificity of the composite panel at time of aGVHD 
onset. ROC curves at day 0 and 7 post-transplant could not be carried out be-
cause of the small sample size.  
 
 
RESULTS 
 
Baseline characteristics of aGVHD patients were similar to the negative controls 
(Table 1).  All aGVHD cases had cutaneous involvement except one who had GI 
pathology (grade II) only.  Six other patients had combined cutaneous and GI 
aGVHD (grade II-IV).  The median time to aGVHD onset was 31 (range 12-77) 
days. 
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Table 1: Baseline characteristics of study population 
Characteristic aGVHD 
N=12 
No GVHD 
N=14 
p value 
Sex, Male, n (%) 8 (66) 8 (57) 0.62 
Age, median (IQR), years  50 
(44-53) 
53  
(43-59) 
0.41 
Haematological diagnoses, n (%) 
Acute myeloid leukaemia 
Chronic myeloid leukaemia 
Aplastic anaemia 
Myeloproliferative neoplasm 
Myelodysplastic syndrome 
 
7 (58) 
0 
1 (8) 
1 (8) 
3 (25) 
 
8 (57) 
1 (7) 
2 (14) 
0 
3 (21) 
 
0.68 
Donor type, n (%) 
Related 
Unrelated 
 
3 (25) 
9 (75) 
 
4 (29) 
10 (71) 
 
0.94 
Donor HLA match, n (%) 
10/10  
9/10 
8/10 
 
10 (83) 
1 (8) 
1 (8) 
 
12 (86) 
1 (7) 
1 (7) 
 
0.98 
Conditioning Intensity, n (%) 
Reduced intensity 
 
12 (100) 
 
14 (100) 0.92 
T- cell depletion (in vivo), n (%) 
Alemtuzumab 
Anti-thymocyte Globulin (ATG) 
 
6 (50) 
6 (50) 
 
8 (57) 
6 (43) 
 
0.72 
 
 
Each of the composite biomarker panels were evaluated for their diagnostic utili-
ty of differentiating between no GVHD and biopsy positive aGVHD patients and 
correlate grading of disease severity on samples taken at day 0, 7 and time of 
onset of GVHD post-transplant. 
 
 
 
 
Page 9 of 31
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
  10 
Panel A (Elafin + sIL-2R + sTNFR1) and Panel C (Elafin + HGF + REG3) at day 
0 and 7 post-transplant respectively could not differentiate between aGVHD and 
no GVHD cases. Composite panel E (Elafin + sIL-2Rα + REG3α) measured at on-
set of aGVHD could differentiate between aGVHD and no GVHD patient groups 
(Table 2; Panel A, C & E). 
Table 2: Comparison of composite biomarker panels (A-F) utility in diagnosis and 
predicting severity of aGVHD in T deplete HSCT patients. (Panels A-F; see supple-
mentary for detail)  
 
The composite panel B and D differentiated between severity of aGVHD (Grade 
III-IV) and no GVHD patients at day 0 and 7 post-transplant respectively 
(p<0.01). Composite panel F also categorized the grading of aGVHD at time of 
onset; no aGVHD vs Grade I (p=0.02), no aGVHD vs Grade II (p<0.01), no 
aGVHD vs Grade III and IV aGVHD (p<0.01). (Table 2; Panel B, D & F). 
Panel 
ID 
Patient co-
hort 
Composite Biomarker Panel Time of 
Sample 
p value 
Panel A 
Non GVHD vs 
aGVHD 
[1000x { 720.57 - (27.52 x Elafin) - (21.41 x 
sIL-2Rα) - (173.87x sTNFR1) }] 
Day 0 0.54 
Panel C 
Non GVHD vs 
aGVHD 
[1000x {471.75 + (48.60 x Elafin) - (20.21 x 
HGF) - (231.40x REG3α)}] 
Day 7 0.85 
Panel E 
Non GVHD vs 
aGVHD 
[1000x {(-39444) + (47.23 x Elafin) + (314.96 
x sIL-2Rα) + (128.79x REG3α)}] 
Onset of 
aGvHD 
0.02 
Panel B 
Non GVHD vs 
Grade II [1000x {constant - (86.55 x Elafin) + (1199 x 
sIL-2Rα) - (917.96x sTNFR1)}] 
Day 0 
0.20 
Non GvHD vs 
Grade III & IV 
0.01 
Panel D 
Non-GVHD vs 
Grade II [1000x {constant - (37.75 x Elafin) + (397.93 
x HGF) - (29.67 x REG3α)}] 
Day 7 
0.14 
Non GvHD vs 
Grade III & IV 
0.02 
Panel F 
Non GVHD vs 
Grade II [1000x {constant - (33.63 x Elafin) - (247.78 x 
sIL-2Rα) - (212.29 x REG3α)}] 
Onset of 
aGvHD 
<0.01 
Non GvHD vs 
Grade III & IV 
<0.01 
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ROC curve analysis was undertaken to evaluate specificity and sensitivity of this 
panel. The AUC for this panel at time of aGVHD onset was 0.73 (CI 50-70%, 
p=0.03) with specificity, sensitivity, positive predictive value (PPV) and negative 
predictive value (NPV) of 100%, 55.6%, 100% and 78.9% respectively, sugges-
tive of a diagnostic utility for the panel (Table 3 and Figure 1) . 
 
Table 3: ROC curve analysis of biomarkers to diagnose GVHD in patients at time of 
onset of aGVHD symptoms  
Bio-Markers AUC 95% CI Sensitivity  
(%) 
Specificity  
(%) 
PPV 
(%) 
NPV 
(%) 
p 
value 
Elafin 0.61 0.31-0.90 66.7 80.0 66.7 80.0 0.47 
sIL-2Rα   0.57 0.30-0.84 55.6 80.0 62.5 75.0 0.62 
REG3α 0.52 0.26-0.77 66.7 53.3 46.1 72.72 0.88 
Composite 
panel E 
0.73 0.48-0.99 55.6 100.0 100.0 78.94 0.03 
AUC - area under curve; CI - confidence interval; PPV- positive predictive value; NPV- negative pre-
dictive value; Composite panel E= [1000x {(-39444) + (47.23 x Elafin) + (314.96 x sIL-2Rα) + 
(128.79x REG3α)}] 
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DISCUSSION 
In our pilot study, we have demonstrated the usefulness of composite biomarker 
panels in the prediction of severity and diagnosis of aGVHD in patients undergo-
ing T-cell depleted reduced intensity allogeneic HSCT. A number of small studies 
have investigated multiple proteins as individual potential biomarkers20; however 
none has been validated as a composite diagnostic panel or predictive laboratory 
test for aGVHD to date and there have been no validations of these biomarkers 
in the T-cell deplete HSCT. Chen et al32 identified characteristics of candidate 
biomarkers that should allow (1) ease of testing, (2) a widely available technique 
with good reproducibility, (3) relatively low cost, (4) adequate sensitivity with high 
specificity, (5) predictive value, (6) correlation with severity and (7) correlation 
with treatment response. 
 
There are only few published papers focusing on a composite biomarker panel 
for aGVHD and most were studied in non-T deplete allograft patients. Paczesny 
et al (2009)20 developed a four biomarker panel using HGF, sIL-2Rα, IL8 and 
sTNFR1 with potential diagnostic utility in patients at onset of aGVHD and pro-
vide prognostic information independent of aGVHD severity. August et al 
(2011)33 reported that a panel of three biomarkers including sIL-2 Rα, sTNFR1 
and soluble CD8 is the best screening test with an AUC of 0.77 at Day 15 post-
transplant. Levine et al (2015)34 developed the Ann Arbor scoring system based 
on a composite panel using ST2 (suppression of tumorigenicity-2), sTNFR1 and 
REG3α with potential to predict the development of gastrointestinal aGVHD. 
Simultaneous use of several biomarkers may increase specificity and hence di-
agnostic and/or predictive values for aGVHD.  Combination of tissue-specific and 
Page 12 of 31
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
  13 
systemic biomarkers is likely to be more informative than single biomarkers for 
aGVHD diagnosis.  
 
The utility of composite panel in HSCT patients is further evident by ROC curve 
analysis of composite biomarkers in Panel E with specificity of 100% and sensi-
tivity of 55.6%, at time of aGVHD onset. Depending on specific clinical situation, 
the sensitivity and specificity of the panel can be adjusted using ROC curve anal-
ysis and reference ranges for composite biomarkers could be derived33. For ex-
ample, the sensitivity of the panel improves to 66.7% with specificity of 86.7% 
providing PPV of 75.0% and NPV of 81.2% for diagnosis (Figure 1). Thus, com-
posite biomarkers in Panel E, measured at time of onset of aGVHD, significantly 
differentiated between no GVHD and biopsy positive aGVHD group (all grades) 
in contrast to Panels A and C measured at day 0 and 7 post HSCT. This high-
lights its potential use as an alternative diagnostic tool for aGVHD with an added 
convenience of non-invasive sampling to patients. 
 
Promisingly, composite biomarker Panel B and Panel D analyzed at day 0 and 7 
post-transplant in our pilot study were also able to predict severity of Grades III-
IV aGVHD before onset. These panels could potentially serve as an important 
laboratory tool for pre-emptive modification of immunosuppressive therapy at an 
earlier stage and reduce associated morbidity with severe aGVHD. Our com-
bined biomarker Panel F was also able to accurately predict between all grades 
of aGVHD at time of onset, which could be useful for identifying potential low 
risk patients (mild-moderate aGVHD) and predict prognosis from aGVHD relat-
ed morbidity. 
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  14 
Very limited evidence exists for evaluation of similar biomarkers in patients with 
‘biopsy proven’ aGVHD and previous studies predominantly included patients 
who received non-manipulated or T-replete allogeneic HSCT. T cell depletion 
with drugs like alemtuzumab results in subdued immune responses to inflamma-
tion with increase in homeostatic regulatory T cells (Treg) and decrease in pro-
inflammatory cytokines35. Any biomarker assay based on pro-inflammatory pro-
teins in this setting may not correlate well with diagnosis of aGVHD in theory, 
thus forming our basis of null hypothesis for this study. This is the first reported 
study within T-depleted allogeneic HSCT settings and despite the potential anti-
inflammatory effects of the conditioning regimen, we could reliably report poten-
tial clinical utility of a composite biomarker panel in diagnosis of aGVHD in these 
patients, who otherwise required biopsy for diagnosis. 
 
From an economical perspective, Elafin and REG3α costs €21 per test and 
sTNFR1, HGF, sIL-2Rα analysis cost €14 per test in our centre. Therefore, a 
composite panel using three biomarkers will cost around €55 which is considera-
bly cheaper and cost-effective than combined costs of diagnostic tissue biopsy 
(operator time and skills, tissue processing & reporting); while removing, the risks 
associated with invasive procedures in this immunocompromised patient popula-
tion. Currently these assays are available as research only tests in our centre, 
but performed by state registered biomedical scientists working in NHS laborato-
ries, however not accredited or part of any EQA exercise or sample exchange 
program. The use of these assays, once validated in larger cohort of clinical 
samples in a prospective study, can be implemented by most accredited labora-
tories familiar with automated ELISA methods run by state registered appropri-
ately trained staff.  
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  15 
 
The assay is limited by its relatively labour intensive technique and need for min-
imum number of samples, which can potentially dictate frequency of samples run 
in clinical laboratory practice. This can be reduced by full automation and per-
formed in larger regional diagnostic reference centers for cost effective operation. 
 
Our study is however limited by the small number of patients. Due to the retro-
spective nature of this study, we could not study composite biomarker trends to 
assess any correlation with severity of disease, subsequent response to therapy 
and its impact on survival. This would be an interesting research question in a 
larger prospective study and could help answer its usefulness in serial measure-
ments of biomarkers to help guide withdrawal of immunosuppression. 
Conclusion 
The use of composite panels is more useful than individual markers. This is again 
demonstrated with panels of composite biomarker proposed in this pilot study, 
providing an improvement in the sensitivity and specificity of diagnosis of aGVHD 
as well as predicting disease severity in T deplete HSCT. Larger studies are still 
required to validate their findings and assess its potential impact on non-relapse 
mortality (NRM) and overall survival (OS) with early aGVHD diagnosis. 
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Take Home Messages (Key Points): 
1. Acute Graft versus host disease (aGVHD) is an unpredictable and potentially de-
bilitating complication of allogeneic stem cell transplants (HSCT). No validated 
diagnostic blood test for aGVHD currently exists, although multiple blood proteins 
have been described as potential biomarkers of aGVHD, mainly in HSCT treated 
with T-cell replete conditioning regimens. 
2. Composite serum biomarker panels developed using logistic regression model-
ling of HGF, Elafin, sIL-2Rα , sTNFR1, and REG3α, in this retrospective pilot 
study of T-cell depleted HSCTs reported for the first time, successfully predicted 
severe aGVHD at early time points of Day 0 and Day 7 post-transplant and diag-
nosed onset of acute GVHD with a high positive and negative predictive value. 
3. The use of composite panels is more useful than individual markers. Once vali-
dated in larger prospective studies, these composite biomarker panels can be po-
tentially used as an alternative diagnostic tool for aGVHD, with an added conven-
ience of cost effective non-invasive sampling, and an important laboratory tool for 
pre-emptive modification of immunosuppressive therapy at an earlier stage and 
reduce associated morbidity with severe aGVHD. 
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Legends: 
Figure 1: ROC curve analysis of composite biomarker Panel E:  
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  23 
The area under curve (AUC) result for the composite panel at time of onset of aGVHD is 
73%, with specificity of 100% and sensitivity of 55.6% (CI 50-70%, p=0.03). The sensitiv-
ity of the panel improves to 66.7% with specificity of 86.7% with positive predictive value 
(PPV) of 75.0% and negative predictive value (NPV) of 81.2% for diagnosis. 
Abbreviations:  
aGVHD - acute Graft vs Host disease; ROC- Receiver operating characteristics 
NPV - Negative predictive value; PPV- Positive predictive value 
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Figure 1: ROC curve analysis of composite biomarker Panel E  
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SUPPLEMENTARY DATA 
 
Table A: Composite Panel A between no GVHD and aGVHD biopsy positive at day 0 
post-transplant 
Biomarkers Coefficient 
Estimate X 10-3 
Standard error 
X 10-3 
Z value P value 
Composite panel A 720.57 1173 0.61 0.54 
Elafin -27.52 41.88 -0.66 0.51 
sIL-2Rα* -21.41 284.86 -0.08 0.94 
sTNFR1** -173.87 405.56 -0.43 0.67 
Composite panel A = [1000x { 720.57 - (27.52 x Elafin) - (21.41 x sIL-2Rα) - (173.87x 
sTNFR1) }]  
*sIL-2Rα: Soluble Interleukin-2 Receptor-α  
**sTNFR1: Soluble Tumour Necrosis Factor Receptor 1 
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Table B: Composite Panel B between groups by GVHD grading in aGVHD biopsy positive 
group at Day 0 post-transplant 
Biomarkers Coefficient Estimate 
X 10-3 
Standard 
error X 10-3 
Z value P value 
No GVHD  Vs Grade I 413.02 (constant 1) 937.61 0.44 0.65 
No GVHD Vs Grade II 1257 (constant 2) 982.19 1.28 0.20 
No GvHD Vs Grade 
III and IV 
2665 (constant 3) 1098.78 2.42 0.01 
Individual biomarkers using ordinal logistic regression as best fit model 
Elafin -86.55 60.22 -1.43 0.15 
sIL-2Rα*  1199 668.80 1.79 0.07 
sTNFR1** -917.96 711.32 -1.29 0.19 
Composite panel B= [1000x {constant - (86.55 x Elafin) + (1199 x sIL-2Rα) - (917.96x 
sTNFR1)}]  
*sIL-2Rα: Soluble Interleukin-2 Receptor-α  
**sTNFR1: Soluble Tumour Necrosis Factor Receptor 1 
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Table C: Composite Panel C between non-GVHD and aGVHD biopsy positive at Day 7 
post-transplant 
Biomarkers Coefficient 
Estimate X 10-3 
Standard error 
X 10-3 
Z value P 
Value 
Composite panel C 471.75 2593 0.18 0.85 
Elafin 48.60 33.41 1.45   0.14 
HGF* -20.21 561.88 -0.03 0.97 
REG3α** -231.40 278.48 -0.83 0.40 
Composite panel C = [1000x {471.75 + (48.60 x Elafin) - (20.21 x HGF) - (231.40x 
REG3α)}] 
*HGF: Hepatocyte Growth Factor 
**REG3α: Regenerating islet-derived 3-α 
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Table D : Composite Panel D between groups by grading in aGVHD biopsy positive 
group at Day 7 post-transplant 
Biomarkers Coefficient 
Estimate X 10-3 
Standard error  
X 10-3 
Z  
value 
P 
Value 
No GVHD Vs Grade 1 778.98 (constant 1) 1071 0.79 0.46 
No GVHD Vs Grade 2 1611 (constant 2) 1112 1.45 0.14 
No GvHD Vs Grade 3 
and 4 
2691 (constant 3) 1236 2.13 0.02 
Individual biomarkers using ordinal logistic regression as best fit model 
Elafin -37.75 21.76 -1.73 0.08 
HGF* 397.93 556.02 0.71 0.47 
REG3α** -29.67 58.96 -1.01 0.31 
Composite panel D = [1000x {constant - (37.75 x Elafin) + (397.93 x HGF) - (29.67 x 
REG3α)}] 
*HGF: Hepatocyte Growth Factor. 
**REG3α: Regenerating islet-derived 3-α  
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Table E : Composite Panel E between non-GVHD and aGVHD biopsy positive at time of 
onset of aGVHD 
Biomarkers Coefficient 
Estimate X 10-3 
Standard error 
X 10-3 
Z 
value 
P 
Value 
Comp site panel E -39444 1698 -2.32 0.02 
Elafin 47.23 28.44 1.66 0.09 
sIL-2Rα*  314.96 232.33 1.35 0.17 
REG3α** 128.79 99.62 1.29 0.19 
Composite panel E = [1000x {(-39444) + (47.23 x Elafin) + (314.96 x sIL-2Rα) + 
(128.79x REG3α)}]  
*sIL-2Rα: Soluble Interleukin-2 Receptor-α 
**REG3α: Regenerating islet-derived 3-α  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 29 of 31
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
Table F : Composite Panel F between groups by grading in aGVHD biopsy positive group at 
time of onset of aGVHD  
Biomarkers Coefficient 
Estimate X 10-3 
Standard error 
X 10-3 
Z value P 
Value 
Non- GVHD  Vs Grade 1 3797 (constant 1) 1699 2.23 0.02 
Non-GVHD Vs Grade 2 4904 (constant 2) 1852 2.64 <0.01 
Non- GVHD Vs Grade 3 
and 4 
6167 (constant 3) 2048 3.01 <0.01 
Individual biomarkers using ordinal logistic regression as best fit model 
Elafin -33.63 18.09 -1.85 0.06 
sIL-2Rα*   -247.78 209.24 -1.18 0.23 
REG3α** -212.29 155.14 -1.36 0.17 
Composite panel F= [1000x {constant - (33.63 x Elafin) - (247.78 x sIL-2Rα) - (212.29 x 
REG3α)}]   
*sIL-2Rα: Soluble Interleukin-2 Receptor-α 
**REG3α: Regenerating islet-derived 3-α  
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Grading Criteria of Acute Graft-versus-Host Disease  
(Modified Glucksberg criteria) 
Stage  Skin  Liver  GI Tract 
I Maculopapular rash 
<25% of body surface 
area (BSA) 
Bilirubin 35-50µm/l  
 
<1000ml diarrhoea/day; 
 Nausea/Vomiting; anorexia 
II Maculopapular rash 
25-50% of BSA 
Bilirubin 51-100µm/l  
 
1000mL-1500mL diarrhoea/day 
III Maculopapular rash >50% 
BSA or generalized 
erythroderma 
Bilirubin 101-250µm/l  
 
>1500mL diarrhoea/day 
 
IV Generalized erythroderma 
with bullous formation and 
desquamation 
Bilirubin >250µm/l  
 
Severe abdominal pain with  
or without ileus 
 
Overall  acute GVHD Grade  
Grade  Skin Stage  Liver Stage  Gut Stage  
I  1-2  0  0  
II  1-3  1  1  
III  2-3  2-3  2-4 
IV  4  4  
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